Research Analysts’ Recent Ratings Changes for Bruker (BRKR)

by · The Markets Daily

Bruker (NASDAQ: BRKR) has recently received a number of price target changes and ratings updates:

  • 12/15/2025 – Bruker had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/15/2025 – Bruker had its price target raised by analysts at Wells Fargo & Company from $48.00 to $55.00. They now have an “overweight” rating on the stock.
  • 12/15/2025 – Bruker had its price target raised by analysts at Barclays PLC from $45.00 to $55.00. They now have an “overweight” rating on the stock.
  • 12/15/2025 – Bruker had its price target raised by analysts at JPMorgan Chase & Co. from $50.00 to $55.00. They now have an “overweight” rating on the stock.
  • 12/15/2025 – Bruker had its price target raised by analysts at Bank of America Corporation from $43.00 to $60.00. They now have a “buy” rating on the stock.
  • 12/10/2025 – Bruker was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating. They now have a $60.00 price target on the stock.
  • 12/9/2025 – Bruker is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $40.00 price target on the stock.
  • 12/9/2025 – Bruker is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $40.00 price target on the stock.
  • 12/8/2025 – Bruker was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
  • 12/1/2025 – Bruker had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/25/2025 – Bruker had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/20/2025 – Bruker was given a new $60.00 price target on by analysts at Redburn Partners.
  • 11/20/2025 – Bruker was upgraded by analysts at Rothschild Redb to a “strong-buy” rating.
  • 11/20/2025 – Bruker is now covered by analysts at Rothschild & Co Redburn. They set a “buy” rating and a $60.00 price target on the stock.
  • 11/19/2025 – Bruker had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/13/2025 – Bruker had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/5/2025 – Bruker had its price target lowered by analysts at Wells Fargo & Company from $50.00 to $48.00. They now have an “overweight” rating on the stock.
  • 11/4/2025 – Bruker had its “hold” rating reaffirmed by analysts at Cowen Inc.
  • 11/4/2025 – Bruker had its price target raised by analysts at UBS Group AG from $40.00 to $43.00. They now have a “neutral” rating on the stock.
  • 11/4/2025 – Bruker had its price target raised by analysts at Barclays PLC from $40.00 to $45.00. They now have an “overweight” rating on the stock.
  • 11/4/2025 – Bruker had its price target raised by analysts at TD Cowen from $40.00 to $42.00. They now have a “hold” rating on the stock.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s dividend payout ratio is -125.00%.

Insider Buying and Selling

In other Bruker news, Director John A. Ornell sold 6,233 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. The trade was a 15.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.30% of the stock is currently owned by corporate insiders.

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Further Reading